Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-01 · accession 0001737287-25-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-05 | 2025-03-01 | ALLO | Beneski Benjamin Machinas | SVP, Chief Technical Off | A - Grant | $0.00 | +31.8K | 224.0K | +17% | $0 |
| D | 2025-03-05 | 2025-03-01 | ALLO | Beneski Benjamin Machinas | SVP, Chief Technical Off | A - Grant | $0.00 | +112.3K | 112.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-01 | A | A | 31,755 | $0.00 | 223,995 | D | — | — | |
| 2 | Derivative | Stock Option (Right to buy) | 2025-03-01 | A | A | 112,339 | $0.00 | 112,339 | D | $1.80 · — to 2035-03-01 | 112,339 Common Stock | (F1) 25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. |